About Novai
Novai is a company based in Reading (United Kingdom) founded in 2019 by Francesca Cordeiro and Aman Khan. Novai has raised $3.36 million across 2 funding rounds from investors including Conduit Connect, Ascension and SFC Capital. The company has 18 employees as of March 31, 2024. Novai offers products and services including DARC Technology, Patient Resources, and Clinical Trials Services. Novai operates in a competitive market with competitors including Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others.
- Headquarter Reading, United Kingdom
- Employees 18 as on 31 Mar, 2024
- Founders Francesca Cordeiro, Aman Khan
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Novai Ltd
- Date of Incorporation 12 Feb, 2020
- Jurisdiction READING, BERKSHIRE
-
Annual Revenue
$291.91 K (USD)0as on Feb 28, 2021
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$3.36 M (USD)
in 2 rounds
-
Latest Funding Round
$2.72 M (USD), Seed
Oct 09, 2021
-
Investors
Conduit Connect
& 2 more
-
Employee Count
18
as on Mar 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Novai
Novai offers a comprehensive portfolio of products and services, including DARC Technology, Patient Resources, and Clinical Trials Services.
AI algorithm for early detection of eye and brain diseases in patients.
Tools empowering patients with disease prevention and management information.
Services aiding clinicians and pharma in ophthalmic drug trials and analysis.
People of Novai
Unlock access to complete
Funding Insights of Novai
Novai has successfully raised a total of $3.36M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $2.72 million completed in October 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Novai
Novai has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Conduit Connect, Ascension and SFC Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital is provided to impact-driven startups.
|
Locked | Locked | Locked | |
|
Ascension is recognized as a venture capital firm focused on early-stage tech investments.
|
Locked | Locked | Locked | |
|
Introductions between investors and early-stage companies are facilitated for funding.
|
Locked | Locked | Locked |
Investor details for Novai
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Novai
Investment portfolio details for Novai
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Novai
Detailed financials for Novai
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Novai Comparisons
Peer comparison for Novai
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Novai
Novai operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Developer of small molecule therapeutics for endocrine and CNS disorders
|
|
| Locked | Locked | Locked |
Small molecule drugs for rare diseases are developed.
|
|
| Locked | Locked | Locked |
Therapies for neurological and neuropsychiatric diseases are developed.
|
|
| Locked | Locked | Locked |
Genetically engineered cell therapies are developed for multiple disorders.
|
Detailed competitors of Novai
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Novai
Complete news archive for Novai
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Novai
Novai was founded in 2019 and raised its 1st funding round 1 year after it was founded.
Novai is headquartered in Reading, United Kingdom.
Novai is a funded company, having raised a total of $3.36M across 2 funding rounds to date.
As of Mar 31, 2024, the latest employee count at Novai is 18.
Annual revenue of Novai is $291.91K as on Feb 28, 2021.
Novai was founded in 2019 in Reading, United Kingdom, focusing on biotechnology for drug development. DARC technology, a retinal biomarker powered by AI, is utilized to advance therapeutics for age-related macular degeneration, retinal conditions, and neurological disorders. Biologics are also being developed to regulate cellular disease activity in multiple sclerosis, Alzheimers disease, Parkinsons disease, diabetes mellitus, and cancer.
Novai's top competitors include Jazz Pharmaceuticals, PTC Therapeutics and Neurocrine.
Novai offers DARC Technology, Patient Resources, and Clinical Trials Services.
Novai has 3 investors. Key investors include Conduit Connect, Ascension, and SFC Capital.